Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-17

Study Completion Date

2020-03-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to compare the pharmacokinetic(s) of K-877 and CSG452 when each drug is administered alone and when both are administered together.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02276001

Healthy

COMPLETED PHASE1

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02275988

Healthy

COMPLETED PHASE1

Drug-Drug Interaction Study in Healthy Adult Volunteers

NCT02275962

Healthy

COMPLETED PHASE1

Drug-Drug Interaction Study in Health Adult Volunteers

NCT02273986

Healthy

COMPLETED PHASE1

A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers

NCT05009368

Health, Subjective

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

K-877 & CSG452

K-877 Single dose on Day 1 and Day 15 CSG452 Repeat dose on Day 2 Through Day 15

Group Type EXPERIMENTAL

K-877

Intervention Type DRUG

K-877 tablets

CSG452

Intervention Type DRUG

CSG452 tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

K-877

K-877 tablets

Intervention Type DRUG

CSG452

CSG452 tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject provides written informed consent before any study-specific evaluation is performed.
* Subject is a healthy adult male or female volunteer between the ages of 18 and 45 years, inclusive, at Screening.
* Subject has a BMI of 18 to 30 kg/m2, inclusive, at Screening.

Exclusion Criteria

* Subject has clinically relevant abnormalities at Screening or at Check-in assessments.
* Subject is pregnant or breastfeeding or intends to become pregnant within 30 days after the last dose of study drug.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes